



**BENZONATATE- benzonatate capsule**  
**PD-Rx Pharmaceuticals, Inc.**

-----  
**Benzonatate Capsules, USP**  
**100 mg and 200 mg**  
**Rx Only**

**DESCRIPTION**

Benzonatate, a non-narcotic antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaocacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.



Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP.

Benzonatate Capsules also contain: D&C Yellow No. 10, gelatin, glycerin, methylparaben sodium and propylparaben sodium.

**CLINICAL PHARMACOLOGY**

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

**INDICATIONS AND USAGE**

Benzonatate is indicated for the symptomatic relief of cough.

**CONTRAINDICATIONS**

Hypersensitivity to benzonatate or related compounds.

## **BOXED WARNING**

### **Hypersensitivity**

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.

### **Psychiatric Effects**

Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs.

### **Accidental Ingestion and Death in Children**

Keep benzonatate out of reach of children.

Accidental ingestion of benzonatate resulting in death has been reported in children below age 10.

Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).

## **PRECAUTIONS**

Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g., procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

### **Information for Patients:**

Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush benzonatate capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.

Keep benzonatate out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.

Overdosage resulting in death may occur in adults.

Do not exceed a single dose of 200 mg and a total daily dose of 600 mg. If you miss a dose of benzonatate, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate at one time.

## **Usage in Pregnancy:**

Pregnancy Category C.

Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.

## **Nursing Mothers:**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzonatate is administered to a nursing woman.

## **Carcinogenesis, Mutagenesis, Impairment of Fertility:**

Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate.

## **Pediatric Use:**

Safety and effectiveness in children below the age of 10 has not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

## **ADVERSE REACTIONS**

Potential Adverse Reactions to benzonatate may include:

**Hypersensitivity reactions** including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

**CNS:** sedation; headache; dizziness; mental confusion; visual hallucinations.

**GI:** constipation, nausea, GI upset.

**Dermatologic:** pruritus; skin eruptions.

**Other:** nasal congestion; sensation of burning in the eyes; vague "chilly" sensation; numbness of the chest; hypersensitivity.

Deliberate or accidental overdose has resulted in death, particularly in children.

## **OVERDOSAGE**

Intentional and unintentional overdose may result in death, particularly in children.

The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

## **Signs and Symptoms:**

The signs and symptoms of overdose of benzonatate have been reported within 15 to 20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.

CNS stimulation may cause restlessness and tremors, which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.

### **Treatment:**

In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.

Do not use CNS stimulants.

### **DOSAGE AND ADMINISTRATION**

Adults and Children over 10 years of age:

Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given.

**Benzonatate should be swallowed whole.** Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.

### **HOW SUPPLIED**

Benzonatate Capsules, USP are available as:

**100 mg**(oval, yellow) soft gelatin capsules with imprint "A5".

NDC 43063-980-30 Bottles of 30

NDC 43063-980-01 Bottles of 100

NDC 43063-980-82 Bottles of 500

**200 mg**(oblong, yellow) soft gelatin capsules with imprint "A6".

NDC 43063-979-01 Bottles of 100

**Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].** Dispense in tight, light-resistant container as defined in the USP.

**To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Limited at 1-866-210-9797 or FDA at 1-800-FDA-1088 or**

[www.fda.gov/medwatch](http://www.fda.gov/medwatch)

**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 100 mg**

**Benzonatate**  
**Capsules, USP**  
**100 mg**  
**Rx only**

Each capsule contains:  
BENZONATATE, USP 100 mg  
USUAL DOSAGE:  
See packaged insert for  
dosage information.  
Store at 20°-25°C (68°-77°F)  
excursions permitted to 15° to  
30°C (59° to 86°F) [See USP  
Controlled Room Temperature].  
**Dispense in a tight,  
light-resistant container  
as defined in the USP.**  
**KEEP TIGHTLY CLOSED**

**NDC 43063-980-01**

**pxl**

**BENZONATATE**

**100 mg**

**100 Capsules**

**Rx Only**

3 43063 98001 9

**Marketed and Packaged By:**  
PD-Rx Pharmaceuticals, Inc  
Oklahoma City, OK 73127

**Manufactured by:**  
Swiss Caps AG  
Kirchberg, Switzerland

Lot # Z9Z99

Exp Date 11/2020

GTIN: 10343063980019  
SNO: Z9Z990002  
EXP: 201130  
LOT: Z9Z99


**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 200 mg**

**Benzonatate**  
**Capsules, USP**  
**200 mg**  
**Rx only**

Each capsule contains:  
 BENZONATATE, USP 200 mg  
 USUAL DOSAGE:  
 See package insert  
 for dosage information.  
 Store at 20° to 25°C (68° to 77°F)  
 excursions permitted to 15° to  
 30°C (59° to 86°F) [See USP  
 Controlled Room Temperature].  
 Dispense in a tight,  
 light-resistant container  
 as defined in the USP.  
**KEEP TIGHTLY CLOSED**



**NDC 43063-979-01**



# BENZONATATE

## 200 mg

**100 Capsules**

Rx Only

**Marketed and Packaged By:**  
 PD-Rx Pharmaceuticals, Inc  
 Oklahoma City, OK 73127  
 1-405-942-3040 v.8.19.0

**Manufactured by:**  
 Swiss Caps AG  
 Kirchberg, Switzerland



GTIN: 00343063979013  
 SNO: K21E14000061  
 EXP: 09/2022  
 LOT: K21E14

## BENZONATATE

benzonatate capsule

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:43063-980(NDC:62332-426)
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>BENZONATATE</b> (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR)	BENZONATATE	100 mg

### Inactive Ingredients

Ingredient Name	Strength
<b>D&amp;C YELLOW NO. 10</b> (UNII: 35SW5USQ3G)	
<b>GELATIN, UNSPECIFIED</b> (UNII: 2G86QN327L)	
<b>GLYCERIN</b> (UNII: PDC6A3C0OX)	
<b>METHYLPARABEN SODIUM</b> (UNII: CR6K9C2NHK)	
<b>PROPYLPARABEN SODIUM</b> (UNII: 625NNB0G9N)	

### Product Characteristics

<b>Color</b>	yellow	<b>Score</b>	no score
<b>Shape</b>	OVAL	<b>Size</b>	9mm
<b>Flavor</b>		<b>Imprint Code</b>	A5

**Contains****Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:43063-980-30	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	07/13/2020	
2	NDC:43063-980-01	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	05/06/2019	
3	NDC:43063-980-82	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	12/13/2019	

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040682	05/01/2018	

**BENZONATATE**

benzonatate capsule

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:43063-979(NDC:62332-427)
<b>Route of Administration</b>	ORAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
<b>BENZONATATE</b> (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR)	BENZONATATE	200 mg

**Inactive Ingredients**

Ingredient Name	Strength
<b>D&amp;C YELLOW NO. 10</b> (UNII: 35SW5USQ3G)	
<b>GELATIN, UNSPECIFIED</b> (UNII: 2G86QN327L)	
<b>GLYCERIN</b> (UNII: PDC6A3C0OX)	
<b>METHYLPARABEN SODIUM</b> (UNII: CR6K9C2NHK)	
<b>PROPYLPARABEN SODIUM</b> (UNII: 625NNB0G9N)	

**Product Characteristics**

<b>Color</b>	yellow	<b>Score</b>	no score
<b>Shape</b>	CAPSULE	<b>Size</b>	16mm
<b>Flavor</b>		<b>Imprint Code</b>	A6
<b>Contains</b>			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:43063-979-01	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	05/06/2019	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040682	05/01/2018	

**Labeler** - PD-Rx Pharmaceuticals, Inc. (156893695)

**Registrant** - PD-Rx Pharmaceuticals, Inc. (156893695)

## Establishment

Name	Address	ID/FEI	Business Operations
PD-Rx Pharmaceuticals, Inc.		156893695	repack(43063-979, 43063-980)

Revised: 7/2023

PD-Rx Pharmaceuticals, Inc.